Dr. Burgess on Treatment Considerations for PARP Inhibitors in Prostate Cancer
Earle Burgess, MD, discusses treatment considerations for PARP inhibitor use in patients with prostate cancer.
Earle Burgess, MD, discusses treatment considerations for PARP inhibitor use in patients with prostate cancer.
No significant difference in time to treatment was found between White and Black patients with bladder cancer, but there remained a difference in treatment outcomes.
David A. Braun, MD, PhD, highlights recent data focused on nivolumab plus cabozantinib in patients with non–clear cell renal cell carcinoma.
UW Health experts advocate for more women in leadership positions and discuss the need to cultivate diversity to reduce disparities in cancer care.
Angela Jia, MD, PhD, discusses the current standing of metastasis-directed radiotherapy in prostate cancer and identifies some lingering questions surrounding the modality.
Robert Wang, MD, discusses the presently limited utility of using molecular imagining with quantitative thresholds in distinguishing RCC from oncocytic renal masses.
Ronan J. Kelly, MD, MBA, discusses the significance of the FDA approval of trastuzumab deruxtecan for pretreated, advanced HER2-positive solid tumors.
PURPOSE Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)–directed antibody-drug conjugate approved in HER2-expressing breast and gastric cancers and HER2-mutant non–small-cell lung…
In a recent study, researchers at Huntsman Cancer Institute found a trend in families with male infertility: an increased risk of certain cancers.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
The European Medicines Agency has validated an application for nivolumab plus ipilimumab for frontline MSI-H/dMMR metastatic colorectal cancer.